cyrilzakka/clinical-trials huggingface dataset:
Safety And Efficacy Of Topical Platelet Rich Plasma And Thrombin Coagulum

The aim of this study is to

* To evaluate the safety and tolerability of Platelet Rich plasma(PRP)/Thrombin mixture in treating chronic venous ulcers
* To evaluate efficacy of PRP/Thrombin mixture in treating chronic venous ulcers

Study rationale

In normal wound healing, platelets activate macrophages to produce endogenous platelet derived growth factor (PDGF) and other growth factors which are responsible for would healing. In chronic wounds, macrophage activation is suppressed which leads to an inappropriate growth factor response causing failure of positive autocrine feedback loop which normally controls the healing process. The regular application of exogenous PRP and Thrombin, to chronic wounds, restores the autocrine feedback loop of tissue repair which appears to accelerate the normal cascade of tissue repair

Objectives

* To evaluate the safety and tolerability of PRP/Thrombin mixture in treating chronic venous ulcers
* To evaluate efficacy of PRP/Thrombin mixture in treating chronic venous ulcers

Eligibility Criteria:
Inclusion Criteria:

* Willing and able to give written informed consent
* Age 18 years to 75 years.
* Both males and females.
* Ankle branchial index of 0.8 or above.

Exclusion Criteria:

* Diabetics will be excluded as the Ankle Branchial Index (ABI) result is considered an unreliable due the possible presence of arteriosclerotic plaques (lead pipe rigidity).
* Patients who have participated in experimental drug studies within 30 days of entering this study.
* receiving chemotherapy or radiotherapy for malignant diseases or any other indication
* Patients taking corticosteroids or other immunosuppressive medications
* Clinically malnourished patients or those with recent (last 4 weeks without treatment) serum albumin of less than 30g/l.
* Patients with current or past history of acute deep vein thrombosis.
* Patients with current signs and/or symptoms of cardiac, renal or hepatic failure. Renal failure defines as Creatinine
* Patients with signs and/or symptoms of peripheral neuropathy.
* Patients with signs and/or symptoms of ATROPHIE BLANCHE or other conditions associated with non-chronic venous insufficiency ulceration of the lower leg.
* Patients with signs and/or symptoms of immunocompromized sates or recent (last 4 weeks ) T cell subset (CD4) count of less than 200 cells / ml.
* Patients showing clinical signs and/or symptoms of anaemia or current or recent(last 4 weeks without treatment) haemoglobin level of less than 8g/dl
102 Annual Pap Smear Screening Database Maintenance Project

This study aimed to evaluate the subsequent cancer risks, including gynecological cancers and malignancies at other sites, after the detection of screening positives and the diagnosis for primary cervical cancer.


Eligibility Criteria:
Inclusion Criteria:

* Citizens in Taiwan
* Women who attended screening, or who were diagnosed as cervical cancer
* Women who did not attend screening for at least 6 years

Exclusion Criteria:

* Women died before the follow-up initiation
* Women who had received hysterectomy before the follow-up initiation
Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

This study will assess the efficacy and safety of AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)


Eligibility Criteria:
Inclusion Criteria:

* Outpatients with Parkinson's disease (PD), treated with L-Dopa, experiencing dyskinesias for at least three months
* Outpatients who are on a stable anti-parkinsonian treatment regimen for at least four weeks

Exclusion Criteria:

* Surgical treatment for PD
* Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated)
* Advanced, severe or unstable disease (other than PD) or evidence of dementia that may interfere with the study outcome evaluations

Other protocol-defined inclusion/exclusion criteria may apply
naVIGation Invitations Liver surveillANce upTake

This study aims to evaluate the efficacy of Patient Navigators and mailed surveillance invitations on attendance of Hepatocellular Carcinoma (HCC) ultrasound surveillance appointments. The investigators hypothesise that mailed invitations and Patient Navigators will improve attendance at HCC surveillance appointments and increase the proportion of patients diagnosed at an early stage, compared with a control group receiving usual care.

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Despite advances in treatment options, prognosis remains worrying, with 5-year survival rates remaining less than 20%.

Surveillance for HCC involves six-monthly ultrasounds (US) of the liver and has been demonstrated to increase rate of early diagnosis, which translates to improved survival. However, the uptake of HCC surveillance is low internationally; in Western countries, only 20% of patients eligible for HCC surveillance receive a surveillance test.

The current provision of HCC surveillance in the UK is ad hoc: eligible patients have six-monthly ultrasound requested by their clinician (usually a gastroenterologist, hepatologist or hepatology clinical nurse specialist). Patients receive an ultrasound appointment in the post with no formal invitation or information about the surveillance test. Work with focus groups suggests lack of knowledge and fear are barriers to HCC surveillance attendance.

Previous research has shown that patient navigation increased HCC surveillance uptake in an American population. However, there has been no research on interventions aimed at improving surveillance uptake in the UK population.

The study predicts that the mailed invitations and Patient Navigators will improve patient attendance at HCC surveillance and increases the number of patients diagnosed with early-stage HCC, compared with usual care.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* ECOG performance status of 0-2
* Eligible for HCC surveillance as defined by NICE and EASL criteria
* Child Pugh A or B cirrhosis
* Child Pugh C cirrhosis AND on liver transplant waiting list
* High risk chronic hepatitis B

Exclusion Criteria:

* Previous or current diagnosis of HCC
* Child Pugh C cirrhosis
* Frailty (Clinical Frailty Scale \>7)
* Previous liver transplant
Personalised Simulation Technologies for Optimising Treatment in the Intensive Care Unit

This project aims to develop software models describing how critically ill patients respond to changes in their treatment whilst admitted to an Intensive Care Unit (ICU). We will use high performance computers to fit software models to the physiological and treatment data of patients receiving mechanical ventilation.

In the United Kingdom, approximately 142,000 people are admitted to ICU each year. A large proportion, 10 - 20%, of these patients have a life-threatening respiratory illness called Acute Respiratory Distress Syndrome (ARDS). These patients need specialist help with their breathing, from a machine called a ventilator. Only seven out of ten patients will survive this illness and even survival may bring ongoing problems, sometimes for a long time after leaving hospital.

Accurate mathematical and computer models of ARDS, would allow investigation of the illness outside of the ICU and inside the virtual environment of a computer. Different treatments could be simulated on the same 'virtual' patient, or the same treatment on many different patients with varying degrees of illness.

Development of these software models, requires collection of a library of data describing how patients respond to changes in their treatment. An example would be to describe how a patient's blood pressure responds to a change in the settings of their ventilator. The changes to a patient's ventilation would be made as part of the normal care provided by the doctors and nurses looking after them.

Mathematical descriptions have been created before, from simpler data sets which were essentially single snapshots of a patient's condition and treatment. The investigators aim to capture sequences of snapshots over several hours, allowing them to build more accurate models.

Guy's and St Thomas' NHS Foundation Trust (GSTFT) is the clinical partner of the project. Patients would be identified there by clinical researchers, who would then collect the data describing their treatment. This data would be anonymised before adding to the library of data to be shared with academic researchers.

Academic members of the team at the University of Warwick and the University of Nottingham possess the engineering and mathematical expertise needed to develop the complex software models. They also provide the facility of a high performance computing cluster necessary for the difficult process of fitting models to the data.

Once the software models have been built and used to examine the how treatment might be improved, the findings would be shared with clinical staff around the world, through the publication of articles in medical journals. It is possible that the insights gained by the modelling process might inform, change and improve how clinical staff use ventilators to support patients with ARDS.

Eligibility Criteria:
Inclusion Criteria:

* At least 18 years of age
* Patients admitted to GSTFT Intensive Care between the dates 01/01/2010 and 31/03/2019
* Receiving mechanical ventilation

Exclusion Criteria:

* Pregnancy or lactation
Evaluation of the Epidemiological and Psychosocial Outcomes of Liver Graft Recipients Transplanted During Childhood

The main objective of this study is to better characterize the adult population with a history of liver transplantation in pediatric age. In this context, the investigators will use a questionnaire to assess the participants social environment and lifestyle habits and validated scales to assess their alcohol consumption and anxiety levels.

Secondly, the investigators would like to assess the participants knowledge of their disease, their experience of the transition period from pediatrics to adult medicine, and their compliance with medication.

Outcomes after pediatric liver transplantation have improved in recent years, thanks to improvements in surgical techniques, immunosuppressive drugs and postoperative management in pediatric hepatology departments. For some diseases, transplantation has become the only way to save the lives of these children, or to ensure them a better quality of life.

Indications for pediatric liver transplantation can be categorized as follows: Cholestatic condition, hepatitis, metabolic diseases, tumors and orther conditions such as Gestational alloimmune liver disease, drug induced liver diseases, ect.

Short- and long-term complications following liver transplantation have been the subject of numerous studies.

These include mainly biliary and vascular complications, rejection and infections (including EBV viral infections, which can lead to post-transplant lymphoproliferative disorder).

A recent study showed that in the long term, only 32% of children with liver transplants had an "ideal outcome" defined as a first allograft stable on immunosuppression monotherapy, normal growth, and absence of common immunosuppression-induced sequelae.

However, there are few studies on the epidemiological and social outcome of pediatric liver transplantation. Our French colleagues have published in 2008 one of the few studies on the subject, which reports notably that young adults with a history of liver transplants in paediatric age were anxious about their future, had lower alcohol consumption than the general population, but that medication compliance remained a challenge to be improved.

The aim of our research project is to broaden our knowledge of the subject by assessing the epidemiological and social impact of pediatric liver transplantation on French-speaking liver transplant patients followed at the Cliniques Universitaires Saint Luc.

Objective data on these points will enable us to reinforce our prevention and social support measures, and to review our transfer protocols from pediatric to adult medicine.

Eligibility Criteria:
Inclusion Criteria:

* Any patient over 18 years old who received a pediatric liver transplant and who have been followed regularly at the Saint-Luc university clinics is eligible for inclusion in this study provided they speak French/Dutch fluently

Exclusion Criteria:

* patients minor (\< 18 years)
The Effects of a Health-social Partnership Program for Discharged Non-frail Older Adults

Previous studies supporting discharged patients are hospital-based which admission criteria tend to include mainly those with complex needs and/or specific disease conditions. This study captured the service gap where these non-frail older patients might have no specific medical problem upon discharge but they might encounter residual health and social issues when returning home.

Objective: To compare the effect of a community-based health-social partnership program with usual care for discharged community-dwelling non-frail older adults on their health-related quality of life, activities of daily living, depressive symptoms, and use of health services.

Design: A randomized controlled trial. Participants: Discharged community-dwelling non-frail older adults from an emergency medical ward in an intervention (n=37) and a control (n=38) group.

Interventions: Discharged older adults were randomized to receive usual care or complex interventions, including structured assessment, health education, goal empowerment, and care coordination supported by a health-social team.

Main measures: The outcomes were measured at pre-intervention (T1) and at three months post-intervention (T2) using the Medical Outcomes Study 12-item Short Form, the Modified Barthel Index and the Geriatric Depression Scale.

Eligibility Criteria:
Inclusion Criteria:

* resided in the service areas of the study hospital,
* were aged 60 or over,
* were cognitively competent with a score greater than 26 in the Montreal Cognitive Assessment Hong Kong version,
* were living at home before and after discharge from the hospital,
* had scores of \<5 on the Clinical Frailty Scale (Note: a patient is considered to be non-frail if they have a score less than 5), and
* were fit for medical discharge

Exclusion Criteria:

* were not able to communicate,
* could not be reached by phone,
* were bed-bound,
* had active psychiatric problems,
* were already engaged in other structured health or social programs, and
* would not be staying in Hong Kong for the three months of the study
Anterior Only Surgery for Management of Traumatic Subaxial Cervical Spine Instability

Classic management of cervical spine sublaxation and dislocation is combined anterior and posterior approach. Unfortunately there are disadvantages for this approach like: increasing morbidity related to each approach, increasing surgical costs, increasing operative time as well as the risk of blood loss.

Anterior approach has the advantages of supine position, less surgical trauma and direct anterior decompression of neural elements. Disadvantages include less mechanical stability and postoperative dysphagia.


Eligibility Criteria:
Inclusion Criteria:

* Acute traumatic cases of adult patients with sub axial cervical spine injury presenting to trauma unit of Assiut university hospital

Exclusion Criteria:

* Patients who need cervical corpectomy.
* Pediatric injuries
Drainage Fluid Biomarkers and Anastomotic Leakage in Colorectal Surgery. A Monocentric Prospective Observational Study

Anastomotic leakage (AL) is one of the most feared intra-abdominal septic complications (IASC) after colorectal surgery. It is defined as the leak of intestinal content due to an anastomotic dehiscence. Incidence ranges from 2% to 20%. AL is usually associated to systemic inflammatory response, even if in some cases the presentation may be subclinical. Therefore, AL is suspected in patients with a strong inflammatory response and can be confirmed by imaging with contrast enhanced computed tomography (CT) scan or water-soluble contrast studies. Nevertheless, imaging has varying sensitivity and specificity and is usually performed once the patient has a clinical evidence, thus potentially delaying the correct timing for surgery. Despite several studies about this topic and the plenty of known risk factors as mentioned above, AL is still not easy to predict. Different tools other than imaging have been studied in order to make diagnosis of AL at an early stage, as the measurement of some biomarkers of inflammation in serum and in drainage fluid.

Biomarkers as white cell blood count (WBC), C-reactive protein (CRP), cytokines (e.g. TNFa, IL-6, IL-1b), markers of ischemia (e.g. lactate) and procalcitonin (PCT) have been used for an early detection of AL and other intra-abdominal septic complications. The primary aim of our study was to assess the role of drainage fluid CRP and lactate-dehydrogenase (LDH) in the early detection of anastomotic leakage.


Eligibility Criteria:
Inclusion Criteria:

* patients aged \>16 y undergoing elective or emergency colorectal surgery for cancer
* patients aged \>16 y undergoing elective or emergency colorectal surgery for diverticular disease
* patients aged \>16 y undergoing elective or emergency colorectal surgery for inflammatory bowel-disease
* patients aged \>16 y undergoing elective or emergency colorectal surgery for reversal of Hartmann's procedure.

Exclusion Criteria:

* patients aged \< 16 y undergoing colorectal surgery;
* patients undergoing Hartman's procedure
Rajavtihi Neuronal Adult Stem Cells Project

To study the success of Oligodendrocyte progenitor cell culture project in Rajavithi Hospital to identify an unlimited clone human neuronal progenitor stem cells from the human brain in the Biomolecular Research Center. This study aims to produce the reproductive clone of neuronal development protocols and advance projects. Neuronal cells such as pyramidal cells, oligodendrocyte, and dopaminergic neuron differentiation protocol/projects for treatment of Alzheimer's disease, Multiple sclerosis, and Parkinson's disease respectively in next phase of clinical trials.


Eligibility Criteria:
Inclusion Criteria:

* Patients who have elective craniotomy or.
* Patients who have elective ventriculostomy surgery or.
* Patients who have elective muscle biopsy or nerve biopsy.
* Patient who have emergency craniectomy for life threatening from emergency medical and surgical conditions such as Brain herniation or head injury

Exclusion Criteria:

* Central nervous system infection for example tuberculous or any bacterial infection, Viral infection, fungal infection.
* Central nervous system Tumor, Malignancy and metastasis.
Effects of Dual-Task Training In Individuals With Alzheimer

The purpose of this study is to investigate the effects of dual-task training on balance, fear of falling, cognitive functions, dual-task performance, depression and quality of life in individuals with Alzheimer.

Eligible participants will be randomized to control or dual-task training group.Control group will receive conventional therapy generally consisted of lower and upper range of motion exercises for 30 minutes 2 times a week for 8 weeks.Dual-task training group will receive exercises involving motor-cognitive dual-task exercises for 30 minutes 2 times a week for 8 weeks.Each participant will be assessed before and after the 8 weeks of treatment.

Eligibility Criteria:
Inclusion Criteria:

* having been diagnosed with mild or moderate Alzheimer's disease
* able to walk with or without assistance
* having sufficient visual and auditory ability to perform the cognitive tests
* being fit to perform physical exercises
* being able to participate in proposed interventions and assessments

Exclusion Criteria:

* having a neurological disorder other than Alzheimer
* having any musculoskeletal problems that can affect balance
* having any contraindication to exercise
* functional limitation or sensory impairment that may affect performance
* major depression
Study of Intravenous RXDX-107 in Patients With Solid Tumors

This is an open-label, Phase I/Ib, dose escalation study of intravenous RXDX-107 administered to subjects with advanced solid tumors. The study is designed to explore the safety, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RXDX-107 and to define a recommended Phase 2 dose (RP2D)


Eligibility Criteria:
Inclusion Criteria:

1. Confirmed relapsed or refractory locally advanced or metastatic solid cancer for whom no standard therapy is considered appropriate, or for whom standard therapy is considered intolerable.
2. \>18 years of age.
3. ECOG performance status of 0 or 1.
4. Life expectancy of at least 3 months.
5. Received the last dose of previous treatment / therapy before Day 1 of cycle 1:

   * 28 days for cytotoxic chemotherapy, immunotherapy, whole brain radiotherapy, anticonvulsive therapy, stereotactic radiosurgery and major surgery
   * 42 days for nitrosureas, mitomycin C, and liposomal anthracycline
   * 14 days for non-cytotoxic cancer therapies and radiotherapy
6. Recovered from all toxic effects (excluding alopecia) of any prior anti-cancer therapy to Grade ≤ 1 or to the baseline laboratory values.
7. Adequate organ function and baseline laboratory values
8. Women of childbearing potential must have a negative serum pregnancy

Phase 1b: Patient must have measurable disease

Exclusion Criteria:

1. Receiving other experimental therapy
2. Known symptomatic brain mets or leptomeningeal involvement
3. Myocardial infarction in the previous 12 weeks. Active ischemia or any other uncontrolled cardiac condition such as angina pectoris, significant cardiac arrhythmia requiring therapy, uncontrolled hypertension, or CHF.
4. Another concurrent illness which would preclude study conduct and assessment, uncontrolled: medical condition, active infection, risk of bleeding, diabetes mellitus, or pulmonary disease, or alcoholic liver disease, or primary biliary cirrhosis.
5. Malignancy within 3 years or active disease requiring treatment other than the target cancer. The exceptions are prostate cancer (Gleason grade \< 6 with normalized PSA levels), treated in situ cervical, breast carcinoma, squamous or basal cell skin cancer.
6. Any condition that may compromise the ability to give written informed consent or to comply with the study protocol.